BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Closed|| Long (1Y)
UBS maintains sell on Ranbaxy
Downside risk continues to be high after FDA bans drugs from the Toansa facility in Punjab. There is uncertainty around Ranbaxy's first to file (FTF) drugs. Cut target to Rs 300 from Rs 500.